brokerages maintain neutral stance on dr reddys labs amid pipeline concerns

Dr. Reddy's Laboratories achieved its highest-ever quarterly revenue for Q2, amounting to ₹1,299.15, which is a 2.12% increase.

Nuvama Institutional Equities appreciates Dr. Reddy's increased focus on developing complex high-value products but emphasizes the need for tangible updates on upcoming drug launches.

Similarly, Jefferies points out the absence of major product launches and the high selling, general, and administrative costs as factors that hinder Dr. Reddy's stock performance. Jefferies also maintains an 'underperform' rating and sets a price target of ₹1,130 for the drugmaker.

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings